Ghanaian cancer research and diagnostics company Yemaachi Biotech has closed a US$3 million seed round to advance its mission of diversifying precision oncology globally. Founded by Yaw Bediako, David Hutchful, Joyce Ngoi, and Yaw Attua-Afari in 2020, Yemaachi uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure strategies which have high efficacy regardless of ethnicity. Dedicated to accelerating precision oncology in Africa and beyond by expanding access to research and diagnostics, Yemaachi has developed a first of its kind pan-African genomic and clinical knowledge base and research platform, which combined with deep clinical partnerships across Africa provides the foundation for innovative products and partnerships to advance new molecular diagnostics and therapeutic targets. Last year, Yemaachi was one of 15 African companies to be selected for the S21 batch of the Y Combinator accelerator, and it has now followed that up with a US$3 million seed round. The round was led by V8 Capital, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.
SOURCE: DISRUPT AFRICA